{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-26-000051","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2026-07-29T10:33:23+00:00","discovered_at":"2026-07-29T10:35:00.282427+00:00","generated_at":"2026-07-29T10:35:05.755622+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific Q2 net sales $5.44B (+7.5% reported); adjusted EPS $0.86 beats guidance","bullets":["Net sales $5.442B, up 7.5% reported (guidance 5.5-7.5%); adjusted EPS $0.86 (guidance $0.82-$0.84).","GAAP EPS $0.61 vs $0.53 YoY; net income $907M.","Cardiovascular segment grew 8.3% reported; MedSurg 5.9%.","Completed $2B accelerated share repurchase (~40M shares); invested $1.5B in MiRus for 34% stake and TAVR option.","Clinical data: FRACTURE IVL trial met endpoints; FARAPULSE PFA showed superiority over drugs in AVANT GUARD."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-26-000051","json":"https://secwatch.observer/filing/0000885725-26-000051.json","markdown":"https://secwatch.observer/filing/0000885725-26-000051.md","text":"https://secwatch.observer/filing/0000885725-26-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/0000885725-26-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572526000051/bsx-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T10:35:05.755622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}